For efficient transfection of cell lines, e.g. A549, Caco-2, CHO-K1, HT-, or U-87 MG, in the Nucleofector® I/II/2b Device
Culture system containing B-ALITM Basal Media (00193516), B-ALITM Differentiation Media (00193517) and B-ALITM SingleQuots® Supplements (00193515) required for air-liquid interface differentiation of bronchial epithelial cells.
Crypreserved ampule of Peripheral Blood Human Natural Killer Cells (CD56 negative immunomagnetic selection) containing ≥ 5 million cells
Cryopreserved ampule of Rat Brain Cortex Neurons containing ≥4 million cells
For medium-throughput transfection of primary cells, e.g. human ADSc or MSC, when working with the 4D-Nucleofector® 96-well Unit.
For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-Nucleofector® X Unit (20 µL format).
-
References - X-Vivo™Overview of relevant references
-
Primary Normal Human Cells and MediaIn Vivo Relevance. In Vitro Results. Updated and revised cell content.
-
X-VIVO Reference Guide 2025A curated list of peer-reviewed articles related to X-VIVO RUO media as used for culturing different primary cells and is a resource for potential consumers to find scientific data.
-
Building Better In Vitro Models Using the Quasi Vivo® SystemOverview webinar providing details and application data using the Quasi Vivo® Systems delivered by Dr. Kelly Davidge, Scientist at Kirkstall Inc.
-
Terms and Conditions TheraPEAK® T-VIVO® Sample Request ProgramTerms and Conditions TheraPEAK® T-VIVO® Sample Requests
-
Instructions for Use – TheraPEAK® X-VIVO® Cell Culture MediumInstructions for how to use the X-VIVO® Media Series
-
TheraPEAK® T-VIVO® Cell Culture Medium – OverviewView or download this document for a comprehensive overview and learn how the chemically defined TheraPEAK® T-VIVO® Medium enhances T-cell culture and accelerates therapy development.
-
TheraPEAK® X-VIVO® Hematopoietic Cell Culture MediumSerum-free, GMP produced medium for cell therapy applications
-
Non-viral Gene Modification for Ex-vivo Cell TherapyIn this interview our Director Transfection R&D discusses the advantages of non-viral transfection technologies for CRISPR- or transposon-based genetic modification cell and gene therapy.
-
A Novel In Vitro Liver Cell Culture Flow System Allowing Long-Term Metabolism and Hepatotoxicity Studies]Manuscript published in Applied In Vitro Toxicology journal describes improvement of CYP450 phenotype of primary cryopreserved hepatocytes using Quasi Vivo® System